DXCM
DexCom, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$88.02
−1.88%Aug 24, 2026, 00:30 UTC
Dexcom and Health2Sync announced a partnership to integrate continuous glucose monitoring with digital chronic disease management for diabetes care in Australia and Singapore.
Source:Aug 20, 2026, 07:18 UTC
Aurora Investment Counsel acquired a new stake in DexCom, Inc., purchasing 34,744 shares valued at approximately $2.34 million in the most recent quarter.
Source:Jul 30, 2026, 20:08 UTC
DexCom reported its fiscal Q2 2026 (April-June) financial results, with revenue up 13.1% year-over-year to $1.3084 billion, operating profit up 49.7% to $318.3 million, and diluted EPS of $0.64.
Jul 27, 2026, 19:59 UTC
The US Food and Drug Administration selected Dexcom as the first manufacturer for its TEMPO pilot program, allowing digital health devices to be offered to Medicare patients before full authorization.
Source:Jul 22, 2026, 21:15 UTC
Dexcom was selected as the first participant in the FDA's TEMPO Digital Health Devices Pilot Program.
Source:Jul 14, 2026, 15:21 UTC
DexCom receives Health Canada authorization for its Dexcom G7 15 Day continuous glucose monitoring system.
Source:Jul 9, 2026, 13:00 UTC
DexCom, Inc. announced it will release its second quarter 2026 financial results and hold a conference call on July 30, 2026.
Source:Jul 7, 2026, 11:10 UTC
Insulet launched its Omnipod 5 automated insulin delivery system in Spain.
Source:Jun 24, 2026, 14:31 UTC
DexCom will roll out its redesigned Stelo app in the United States in July, with plans for global expansion and pediatric clearance.
Source:Jun 16, 2026, 14:56 UTC
DexCom received FDA clearance for its Stelo OTC continuous glucose monitoring system for children aged 2 and older not using insulin.
Source:Jun 12, 2026, 20:15 UTC
The U.S. Food and Drug Administration cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children with diabetes.
Source:Jun 11, 2026, 10:08 UTC
Pharmsource LLC stated it was unaware that the Dexcom glucose sensors it purchased from licensed distributors were slated for destruction, after Dexcom warned that some units were stolen during disposal and resold.
Source:Jun 8, 2026, 18:31 UTC
DexCom reports positive CONNECT trial results for its Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin.
Source:Jun 6, 2026, 18:49 UTC
Dexcom announced study results showing its G7 continuous glucose monitor improved blood sugar control in non-insulin type 2 diabetes patients compared to routine care.
Source: